LON:ETX e-therapeutics (ETX) Share Price, News & Analysis GBX 9 -0.65 (-6.74%) (As of 05/8/2024) Add Share Share Stock Analysis Stock AnalysisHeadlinesInsider Trades About e-therapeutics Stock (LON:ETX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get e-therapeutics alerts:Sign Up Key Stats Today's Range 9▼ 10.7550-Day Range 9▼ 952-Week Range 8▼ 24Volume2.52 million shsAverage Volume758,869 shsMarket Capitalization£52.59 millionP/E RatioN/ADividend Yield3.35%Price TargetN/AConsensus RatingN/A Company Overviewe-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.Read More… Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Receive ETX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ETX Stock News HeadlinesAN2 Therapeutics to Meet With FDA on Epetraborole Development PathNovember 13, 2024 | marketwatch.comPositive Outlook for Akero Therapeutics Driven by Efruxifermin’s Potential and Strategic Clinical ProgramsNovember 11, 2024 | markets.businessinsider.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 21, 2024 | WealthPress (Ad)RBC Capital Releases a Buy Rating on Edgewise Therapeutics (EWTX)November 8, 2024 | markets.businessinsider.comAquestive Therapeutics: Progress in Drug InnovationNovember 6, 2024 | markets.businessinsider.come-therapeutics Announces Business Updates and Interim ResultsOctober 31, 2024 | markets.businessinsider.comEvecxia Therapeutics Announces Successful Completion of Pre-IND Meeting with the FDA Regarding Development of EVX-101 For DepressionOctober 27, 2024 | businesswire.comIterum Therapeutics Shares Soar on FDA's Orlynvah ApprovalOctober 25, 2024 | marketwatch.comSee More Headlines ETX Stock Analysis - Frequently Asked Questions How have ETX shares performed this year? e-therapeutics' stock was trading at GBX 8.24 at the beginning of 2024. Since then, ETX stock has increased by 9.2% and is now trading at GBX 9. View the best growth stocks for 2024 here. How were e-therapeutics' earnings last quarter? e-therapeutics plc (LON:ETX) posted its quarterly earnings results on Tuesday, March, 17th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.03. How do I buy shares of e-therapeutics? Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of e-therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that e-therapeutics investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), B&M European Value Retail (BME), Coats Group (COA), Eurasia Mining (EUA), genedrive (GDR) and Greencore Group (GNC). Company Calendar Last Earnings3/17/2020Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ETX CUSIPN/A CIKN/A Webwww.etherapeutics.co.uk Phone+44-1993-880000FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-10,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.75% Return on Assets-29.10% Debt Debt-to-Equity Ratio0.33 Current Ratio22.20 Quick Ratio20.13 Sales & Book Value Annual Sales£295,000.00 Price / Sales178.27 Cash FlowGBX 1.77 per share Price / Cash Flow5.07 Book ValueGBX 5 per share Price / Book1.80Miscellaneous Outstanding Shares584,330,000Free FloatN/AMarket Cap£52.59 million OptionableNot Optionable Beta0.46 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (LON:ETX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding e-therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share e-therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.